source
- Phase 3 trial shows pre- and post-surgery hormone therapy improves outcomes for high-risk prostate cancerA phase 3 study called PROTEUS evaluated high‑risk, early‑stage prostate cancer patients who were scheduled for surgery. The trial compared a regimen that gave two hormone therapies before and afte…
- RevMed earns standing ovation at ASCO for pancreatic cancer data while Akeso faces cautionAt the American Society of Clinical Oncology meeting, RevMed captured audience attention with data on its pancreatic cancer therapy, earning a rare standing ovation. In contrast, presentations fro…